Measured Wealth Private Client Group’s Protalix BioTherapeutics PLX Stock Holding History

Measured Wealth Private Client Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-38,116	Closed	-$148K	–	138
2020 Q3	$148K	Hold	38,116	–	–	0.07%	134
2020 Q2	$144K	Hold	38,116	–	–	0.08%	121
2020 Q1	$90K	Hold	38,116	–	–	0.07%	100
2019 Q4	$125K	Buy	38,116 +34,304	+900%	+$84.5K	0.08%	102
2019 Q3	$8K	Hold	3,812	–	–	0.01%	133
2019 Q2	$18K	Hold	3,812	–	–	0.01%	200
2019 Q1	$17K	Buy	+3,812	New	+$17.2K	0.01%	174

Other funds holding PLX

BCM

Burrage Capital Management Boston, Massachusetts $99.7M AUM 66.05% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Measured Wealth Private Client Group's PLX Position: Q4 2020 in Review

Measured Wealth Private Client Group sold out of Protalix BioTherapeutics (PLX) in Q4 2020, closing a stake of 38,116 shares — an estimated $148K sold.

Measured Wealth Private Client Group first reported a position in PLX in Q1 2019 and held it in 7 quarters. The position peaked at $148K in Q3 2020. 23 funds tracked by Wall St. Rank hold PLX as of Q4 2020.

Measured Wealth Private Client Group reported no remaining Protalix BioTherapeutics position as of Q4 2020 after selling out during the quarter.
Measured Wealth Private Client Group sold 38,116 Protalix BioTherapeutics shares in Q4 2020, an estimated $148K.
Measured Wealth Private Client Group first reported a position in Protalix BioTherapeutics in Q1 2019 and held it in 7 quarters.
Measured Wealth Private Client Group's Protalix BioTherapeutics position peaked at $148K in Q3 2020.
23 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2020.

Based on Measured Wealth Private Client Group's 13F filing for Q4 2020, filed 20 Jan 2021.